Vanguard Group Inc Celldex Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
A detailed history of Vanguard Group Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,954,590 shares of CLDX stock, worth $101 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,954,590
Previous 3,957,122
0.06%
Holding current value
$101 Million
Previous $80.5 Million
27.04%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding CLDX
# of Institutions
206Shares Held
66.8MCall Options Held
222KPut Options Held
234K-
Kynam Capital Management, LP Princeton, NJ6.1MShares$156 Million13.34% of portfolio
-
Wellington Management Group LLP Boston, MA5.8MShares$148 Million0.03% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$120 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.89MShares$99.5 Million0.2% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.56MShares$90.9 Million1.97% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.2B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...